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ABSTRACT Chronic breathlessness is a disabling syndrome, prevalent in people with advanced chronic
obstructive pulmonary disease (COPD). Regular, low-dose, oral sustained-release morphine is approved in
Australia to reduce symptomatic chronic breathlessness. We aimed to determine the current prescribing
patterns of opioids for chronic breathlessness in COPD in Australian general practice and to define any
associated patient and practitioner characteristics.
Five years (2011 to 2016) of the Bettering the Evaluation and Care of Health database, an Australian
national, continual, cross-sectional study of clinical care in general practice were used. The database
included 100 consecutive clinical encounters from almost 1000 general practitioners annually (n=488100
encounters). Descriptive analyses with subsequent regression models were generated.
Breathlessness as a patient-defined reason for encounter was identified in 621 of 4522 encounters where
COPD was managed. Opioids were prescribed in 309 of 4522 encounters where COPD was managed
(6.8%; (95% CI) 6.1–7.6), of which only 17 were prescribed for breathlessness, and the rest for other
conditions almost entirely related to pain. Patient age (45–64 years versus age 80+ years, OR 1.68;
1.19–2.36), Commonwealth Concession Card holders (OR 1.70; 1.23–2.34) and socioeconomic
disadvantage (OR 1.30; 1.01–1.68) were associated with increased likelihood of opioid prescription at
COPD encounters. The rate of opioid prescriptions rose over the 5 years of study.
In primary care encounters for COPD, opioids were prescribed in 6.8% of cases, but almost never for
breathlessness. These data create a baseline against which to compare changes in prescribing as the
treatment of chronic breathlessness evolves.
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Chronic breathlessness is prevalent across the community, and is mainly related to self-reported
respiratory diseases [1, 2]. Chronic breathlessness syndrome, defined as disabling breathlessness which
persists despite optimal treatment of the underlying pathophysiology [3], is associated with impaired
physical and mental components of quality of life [4]. Primary care is the most common setting for both
its initial presentation and ongoing clinical management [5–7].
The evidence base for the symptomatic reduction of chronic breathlessness has evolved over the last two
decades. A key framework for the assessment and treatment of chronic breathlessness is the Canadian
Thoracic Society ladder [8]. This approach includes reversing treatable causes, instigating evidence-based
nonpharmacological interventions and, if appropriate, pharmacological interventions [9]. The
pharmacological treatment with best evidence for the reduction of chronic breathlessness is regular,
low-dose, sustained-release morphine [10, 11]. The strongest evidence for its effectiveness is in people with
severe breathlessness (modified Medical Research Council breathlessness scale 3 or 4 [12, 13]) and chronic
obstructive pulmonary disease (COPD) [14].
The indication for sustained-release morphine (Kapanol) has recently (February 2019) been extended by
the Australian Therapeutic Goods Administration to include “the symptomatic reduction of chronic
breathlessness in the palliative care of patients with distressing breathlessness due to severe COPD, cardiac
failure, malignancy or other cause. Kapanol should only be used after treatments for the underlying
cause(s) of breathlessness have been optimised and nonpharmacological treatments are not effective” [15].
As this extended license may influence prescribing (both number of prescriptions and drug regimen used),
it is timely to explore the baseline level of use of opioids for breathlessness in general practice.
General practice provides care for the largest number of people with chronic breathlessness [5–7]. These
consultations result in an average of three medications being prescribed for each two consultations where
breathlessness is the reported reason for encounter [5]. Given the approval noted above, knowledge about
both the baseline level and the patterns of, until now, off-label prescribing of low-dose morphine for the
symptomatic reduction of chronic breathlessness is important in the assessment of future patterns of
prescribing.
The primary aim of this study was to define existing patterns of opioid prescribing over time for people
with COPD and breathlessness in Australian general practice. Secondary aims included an exploration of
patient or practitioner characteristics associated with opioid prescribing in people with COPD.
Methods
Design and setting
This study used data from the Bettering the Evaluation and Care of Health (BEACH) project, an
Australian national, cross-sectional study of general practitioners’ (GPs) clinical care [16]. The BEACH
project collects data contemporaneously at the point of care on approximately 100000 nationally
representative GP–patient encounters annually. Each year, a random sample of 1000 GPs chosen from the
Australian Government’s Medicare claims records completed the project. Each GP recorded details of 100
consecutive encounters with consenting patients [17]. These details were recorded on structured paper
forms wherever that encounter occurred (in the GP’s consulting room or home visit, including residential
aged care facilities) with each problem linked to the clinical actions undertaken by the GP. Data are
representative of patient encounters with GPs in Australia [16]. The current study examines the last
5 years of BEACH data (April 2011 to March 2016 inclusive, when data collection for BEACH ceased)
giving a total of almost 500000 encounters.
Data
Data were collected on the patient’s own reported reasons for encounter, directly linked to problems/
diagnoses managed by the GP at the encounter, and consequent clinical actions: medications prescribed,
supplied by the GP or advised for over-the-counter purchase; procedures undertaken; new referrals made;
and any ordering of pathology or imaging investigations [16]. Demographic factors included sex, age and
whether the person held a Commonwealth Concession Card. The latter includes aged pensioners, people
receiving support for long-term disability and people who are unemployed. (In Australia, it is legal for
medical practitioners to charge above the national insurance reimbursement. Practitioners are encouraged
not to charge out-of-pocket payments for people who hold a Concession Card.)
Conditions were coded according to the International Classification of Primary Care version 2 PLUS
(ICPC-2 PLUS) by trained coders and automatically classified to ICPC-2 [18, 19]. Medications were coded
using the Coding Atlas of Pharmaceutical Substances [20], and automatically classified to the Anatomical
Therapeutic Chemical classification [21]. GPs could record the name of the medication, strength, regimen
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and number of repeats. They could also indicate whether this was a new or continuing prescription. To
ensure opioid doses were comparable, oral morphine equivalent doses were calculated for all prescribed
opioids using a single resource [22].
Population and time period
We analysed all encounters in the last 5 years of BEACH data collection (April 2011 to March 2016
inclusive) where COPD was recorded as a problem managed at encounter. We made no distinction
between first presentation of COPD and COPD that had been managed previously.
COPD was defined as ICPC-2 rubric R95 “Chronic Obstructive Pulmonary Disease” [18, 19]. A secondary
interest was to see whether a patient presented with breathlessness as a reason for encounter (i.e. in the
patient’s own words). Breathlessness was defined as ICPC-2 rubric R02 “Shortness of Breath/Dyspnoea” [18,
19]. Opioids were defined as Anatomical Therapeutic Chemical code N02A “Opioids” [21]. A low dose of
opioid was defined as an oral morphine equivalent prescribed daily dose (OMEPDD) of ⩽30 mg [21].
For encounters where COPD was managed, we examined whether opioids were prescribed directly for the
management of COPD or for problems unrelated to COPD (with ICPC codes other than those included
in R95). We also examined whether opioid prescribing was different for patients who had breathlessness as
a stated reason for encounter.
We were able to determine the patient’s relative level of socioeconomic advantage using Socio-Economic
Indexes for Areas (SEIFA) Index of Relative Socio-Economic Advantage and Disadvantage (IRSAD) [23]
based on their residential postcode. A patient was considered to be from a non-English-speaking background
if they reported that they spoke a language other than English as their primary language at home. A person’s
Aboriginal or Torres Strait Islander status (“Indigenous”) was determined by self-report. The remoteness of
each general practice was determined by the Australian Statistical Geography Standard [24].
Statistical analyses
No data were imputed. COPD management rate was examined by patient and GP characteristics. We
compared the opioids prescribed at COPD encounters by those prescribed for the direct management of
COPD to those prescribed for the management of other non-COPD problems also managed at the COPD
encounter. The proportion of COPD encounters at which an opioid was prescribed was examined by GP
and patient characteristics at the univariate level. To determine which patient and GP characteristics were
independently associated with opioid prescribing at COPD encounters, a multivariate logistic regression
was performed with backwards elimination until a parsimonious model was achieved.
Analyses were adjusted for the cluster survey design (100 encounters for each GP) All analyses were
conducted using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). Given multiple comparisons, differences
between point estimates were considered statistically significant if their 95% CIs were not overlapping
(equivalent to p<0.006).
Ethics and consent
The BEACH research program was approved by the Human Research Ethics Committee of the University
of Sydney (2012/130). Only aggregated, de-identified data are presented.
Results
Proportion of COPD-related management at general practice encounters
Of 488100 encounters, 4522 (0.93%) had COPD recorded by the GP as one of the problems managed.
(table 1) The proportion of COPD-related encounters was higher among patients who were male; older;
holding a Commonwealth Concession Card; from an English-speaking background; from a more
socioeconomically disadvantaged area; Indigenous; and known to that GP’s practice. The proportion of
patients managed with COPD was higher in encounters with GPs who themselves were: male; older; and/
or working in nonmajor city practices.
Opioid prescribing at COPD encounters
Of the 4522 encounters where COPD was managed, opioids were prescribed at 309 (6.8%), with 377
prescriptions being written. (table 2 and figure 1) Of the 4522 COPD problems managed, at least one
opioid was prescribed directly for its management on 17 occasions, or 0.38% of the times COPD was
managed. Of the 377 opioid prescriptions at COPD encounters, only 23 (6.1%) were for the direct
management of COPD, whereas 354 (93.9%) were for other (non-COPD) problems. Of the 23 opioid
prescriptions for COPD, 18 (78.3%) were for morphine, whereas morphine comprised only 8.8% of the
354 opioids prescribed for non-COPD-related problems. We were only able to calculate an OMEPDD for
10 of the 23 opioid prescriptions prescribed for COPD, of which 80% were low dose. Of the 354
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prescriptions for non-COPD-related problems, an OMEPDD was calculable for 252, of which 51% were
low dose. The proportion of encounters at which an opioid was prescribed for COPD increased over the
5 years of data together with the proportion for COPD encounters, and opioid prescriptions for
non-COPD problems (figure 2).
TABLE 1 The proportion of encounters where COPD was managed, by patient and general
practitioner (GP) characteristics, 2011–2016 in a representative sample of Australian general
practices










Male 2279 195991 1.16% (1.10–1.22)
Female 2205 287848 0.77% (0.73–0.81)
Age
<25 years 7 94364 0.01% (0.00–0.01)
25–44 years 110 107575 0.10% (0.08–0.12)
45–64 years 1052 132027 0.80% (0.74–0.85)
65–79 years 2140 98142 2.18% (2.07–2.29)
80+ years 1181 51846 2.28% (2.13–2.43)
Commonwealth Concession Card
Yes 3446 200495 1.72% (1.65–1.79)
No 841 246429 0.34% (0.31–0.37)
Language background
English 4002 400671 1.00% (0.96–1.04)
Other language 258 38901 0.66% (0.57–0.75)
Socioeconomic status
Advantaged 2006 288605 0.70% (0.66–0.73)
Disadvantaged 2425 189031 1.28% (1.21–1.35)
Indigenous status
Indigenous 119 8820 1.35% (1.07–1.63)
Non-indigenous 4145 430863 0.96% (0.92–1.00)
Patient new to practice
Yes 136 36470 0.37% (0.31–0.44)
No 4316 444368 0.97% (0.93–1.01)
GP characteristics and clinical practice factors
Sex
Male 2883 278700 1.03% (0.98–1.09)
Female 1639 209400 0.78% (0.73–0.84)
Age
<45 years 920 128300 0.72% (0.66–0.78)
45–54 years 1240 143000 0.87% (0.80–0.93)
55+ years 2342 213900 1.09% (1.03–1.16)
Practice location
Major city 2703 343500 0.79% (0.75–0.83)
Inner regional 1226 95800 1.28% (1.18–1.38)
Outer regional/
remote
585 47500 1.23% (1.09–1.37)
Country of graduation
Australia 3097 323100 0.96% (0.91–1.01)
Overseas 1411 163300 0.86% (0.80–0.92)
Fellow of a college#
Yes 2709 303100 0.89% (0.85–0.94)
No 1773 180500 0.98% (0.92–1.04)
Total 4522 488100 0.93% (0.89–0.96)
Data are presented as n or % (95% CI). #: Fellow of either the Royal Australian College of GPs or the
Australian College of Rural Remote Medicine. All GPs in Australia have to do a post-graduate Fellowship in
order to be registered to practice. This training deals with frequently encountered conditions such as
COPD. All GPs must participate in continuing professional education, although the topics are at the
discretion of GPs.
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When an opioid was prescribed at a COPD encounter pain was the most common indication for its
prescription the three most prevalent clinical indications being back pain (25.0% of problems),
osteoarthritis (17.6%) and pain (general or multiple sites; 13.1%).
Breathlessness was stated as a patient-described reason for encounter in only 621 of 4522 (13.7%) of those
managed for an encounter for COPD, and 37 of 309 (12.0%) in patients with an encounter for COPD
managed with opioids. At COPD encounters with an opioid prescription for a COPD-related problem,
pain was still the most common reason for prescription. However, those people who gave breathlessness as
23 prescriptions written























488 100 clinical encounters
4522/488 100 (0.9%) relate to active managment of COPD
309/4522 (6.8%) encounters where opioids were
prescribed for someone with COPD
354 prescriptions written






FIGURE 1 Flow diagram of a representative sample of Australian general practice adult consultations relating
to opioid prescribing in people with COPD.
TABLE 2 Opioids prescribed at 309 (6.8%) clinical encounters involving patients with COPD
(n=4522) accounting for 0.93% of 488100 clinical encounters reported from this consecutive
case series in Australian general practices








Morphine 31 (8.8%) 18 (78.3%)
Oxycodone 93 (26.3%) 1 (4.3%)
Oxycodone and naloxone 19 (5.4%) 1 (4.3%)
Hydromorphone 9 (2.5%)
Codeine# 74 (20.9%) 1 (4.3%)
Fentanyl 20 (5.6%)




Data are presented as n (%). At the 309 encounters where COPD was managed, there were 312 problems
generating 377 opioid prescriptions: 354 prescriptions for 295 non-COPD problems; and 23 prescriptions
for 17 COPD-related problems. #: alone or in combination.
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a reason for encounter were no more likely to be prescribed opioids than the rest of the population with
COPD. (table 3)
Unadjusted univariate predictors of opioid prescription
Commonwealth Concession cardholders were more likely to be prescribed opioids (7.46% compared to
4.40% for those without a Concession card) (table 3). Otherwise there were no unadjusted univariate
significant differences in the likelihood of opioid prescription by patient characteristic (sex, age, language
background, socioeconomic or Indigenous status, or whether they were new to the practice), by GP
characteristic (sex, age, country of medical graduation or location of practice) or by the presence or
absence of breathlessness as a reason for encounter.
Multivariate logistic regression
All patient and GP characteristics reported in the univariate analyses were included in a multivariate
analysis. After backwards elimination, the final parsimonious multivariate logistic regression model found
that a patient holding a Commonwealth Concession Card, living in a more socioeconomically
disadvantaged area or being aged 45–64 years were all independently associated with an increased
likelihood of opioid prescription at COPD encounters (table 4).
Discussion
Nearly 1% of all GP encounters were related to COPD. However, only a small proportion (6.8%) of these
were prescribed opioids at these encounters. Almost all opioid prescriptions at COPD encounters were for





Management rate of COPD per 1000 encounters
% COPD problems managed with opioids









Year of data collection (April–March)
2010 2011 2012 2013 2014 201520092000 2001 2002 2003 2004 2005 2006 2007 2008
FIGURE 2 The proportion of encounters in which COPD was managed and the encounters at which an opioid
was prescribed for COPD or non-COPD-related problems.
https://doi.org/10.1183/23120541.00299-2019 6
COPD | D.C. CURROW ET AL.
was prescribed for non-COPD-related problems, the most common opioid prescribed for COPD was
morphine. The rate of opioid prescriptions rose over the 5 years of study.
As a descriptive study, it can only define associations. Associations were seen with COPD and
socioeconomic status, explained almost entirely by differential smoking rates by socioeconomic status. In
Australia, these vary by 2.5-fold from the highest to the lowest socioeconomic quintiles. Likewise, it is not
surprising to see demographic differences in GPs’ encounters for people with COPD, given that many
patients age along with their GPs.
This study adds a level of detail not possible from previous large prescribing studies. VOZORIS et al. [25]
reported on the outcomes for 130000 people with COPD who were prescribed opioids. The reason for the
prescription was unavailable in that dataset. This study identifies that the overwhelming majority of opioid
prescriptions in consultations involving management of COPD were given for other pain-related problems.
Our data provide the reason for encounter linked to GP’s clinical management including the very small
proportion who had symptomatic treatment of breathlessness. This may reflect previous reports of poor
GP confidence in managing the symptom of breathlessness [26].
TABLE 3 The proportion of patients with COPD recorded at their clinical encounter who were
















Sex Male (2279) 6.32% 5.25% 7.39%
Female (2205) 7.44% 6.29% 8.58%
Age <45 years (117) 6.84% 2.28% 11.40%
45–64 (1052) 8.46% 6.77% 10.15%
65–79 (2140) 6.82% 5.67% 7.97%
80+ (1181) 5.50% 4.19% 6.82%
Commonwealth
Concession Card
Yes (3446) 7.46% 6.52% 8.40%
No (841) 4.40% 3.02% 5.78%
Socioeconomic status Less advantaged (2425) 5.78% 4.72% 6.85%
More advantaged (2006) 7.84% 6.68% 8.99%






No (4145) 6.90% 6.07% 7.73%
Yes (119) 4.20% 0.62% 7.78%
Patient new to the
practitioner
No (4316) 6.88% 6.08% 7.69%
Yes (136) 5.15% 1.49% 8.80%
GP prescriber characteristics
Sex Male (2883) 6.69% 5.71% 7.68%
Female (1639) 7.08% 5.80% 8.36%
Age <45 (920) 6.52% 4.86% 8.18%
45–54 (1240) 7.34% 5.90% 8.78%
55+ (2342) 6.75% 5.62% 7.87%
Primary medical
degree
Australia (3097) 6.97% 6.02% 7.93%
Elsewhere (1411) 6.59% 5.21% 7.97%
Fellow of the College Yes (2709) 6.61% 5.65% 7.57%
No (1773) 7.22% 5.88% 8.56%
Place of practice Major city (2703) 6.36% 5.40% 7.33%







Yes (621) 5.96% 4.06% 7.86%
No (3901) 6.97% 6.12% 7.83%
Total n=309 6.83% 6.05% 7.62%
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This study covers a period of clinical research where the evidence base for the symptomatic treatment of
chronic breathlessness has evolved rapidly. During the study period several meta-analyses have been
published that help establish a role for regular, low-dose morphine to reduce the intensity of chronic
breathlessness [11, 27]. In response to this growing evidence base, there is now a world’s first registration
for any medication for the symptomatic reduction of chronic breathlessness [28]. As such, this background
rate of prescribing opioids in the presence of breathlessness as the reason for encounter forms an
important baseline against which to evaluate future changes in general practice prescribing.
A longitudinal cohort study in Australia reported that people who were prescribed opioid analgesics for
persistent noncancer pain are less likely to have private health insurance [29]. Our study results correlate
with those findings. The higher opioid prescription rates for people living in more socially disadvantaged
areas reflects trends for opioid prescription in people with persistent noncancer pain in Australia [29].
Strengths
The major strengths of this study are the large number of clinical consultations drawn from a
representative sample of GPs nationally, the coverage of clinical settings included and the quality of the
clinical and demographic information associated with the prescription of opioids. The use of a consecutive
cohort limits selection bias.
Limitations
This study provides cross-sectional data with no further information on the short- or long-term clinical
outcomes from each consultation. This is in contrast to one previous, registry-based study, where
long-term outcomes, including hospitalisations and mortality, were defined by lower- versus higher-dose
opioids in people with oxygen-dependent COPD and, separately, oxygen-dependent interstitial lung
disease [9, 30]. The assessment of chronic breathlessness seeking reversible causes and the use of
nonpharmacological interventions are beyond the scope of the dataset [8, 31]. If patients had multiple
problems, it is possible that they may not identify chronic breathlessness at every encounter, potentially
under-estimating the population of patients in contact with GPs who experience the syndrome.
Application of these findings to other health systems depends on the roles, costs, accessibility and
relationships between primary, secondary and tertiary care. This study was performed in a country with
universal health insurance for permanent residents, with a strong specialist workforce.
Implications for clinical care
Given population rates of modified Medical Research Council 3 or 4 of about 1% [1] and the burden of
disability that chronic breathlessness brings, rates of opioid prescriptions may rise in the coming years
with a world first approval for regular, low-dose, sustained-release morphine for the symptomatic
reduction of chronic breathlessness. As the evidence base is derived only from people with advanced,
progressive diseases and severe chronic breathlessness mainly in tertiary care settings, prescribing in
primary care needs to be followed carefully in pharmacovigilance studies (using these current data as a
baseline) to understand the longer term net effects (i.e. benefits and harms). Further, broadening data
collection to ensure reversible causes contributing to breathlessness have been addressed systematically and
TABLE 4 Final logistic regression model predicting opioid prescription in patients with COPD
managed at their general practitioner encounter









Age (years) 80+ (reference) 1.000
65–79 1.21 0.90 1.65
45–64 1.68 1.19 2.36




Yes 1.70 1.23 2.34
Socioeconomic status More advantaged
(reference)
1.000
Less advantaged 1.30 1.01 1.68
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that evidence-based, nonpharmacological interventions have been employed will help to optimise clinical
outcomes [8, 31].
The other fundamental challenge highlighted by these data is that either people with COPD appear not to
seek help for chronic breathlessness, or if they do, there is no clinical response, or, this is not seen as
sufficiently clinically relevant to be documented by the clinician. Only 13.7% (621 of 4255) of people with
COPD had breathlessness documented as a reason for encounter. A proportion of the patients whose care
is reflected in this study will have chronic breathlessness that will cause ongoing limitations in activities in
daily living [32, 33]. Despite increased evidence for the symptomatic treatment of chronic breathlessness,
pessimistic expectations of both the patient and the clinician may engender a degree of therapeutic
nihilism. A recent observational cohort examining the prevalence chronic breathlessness in people with
COPD found that 53% had persistent disabling breathlessness despite optimal treatment, yet few or no
interventions had been documented [34]. This is consistent with another study highlighting that further
management of chronic breathlessness is not regarded as necessary [35]. Our study, again, highlights the
need for clinicians to appropriately diagnose chronic breathlessness and record its effect on the patient.
Implications for future research
This study creates an objective baseline for the prescription of opioids for the management of COPD.
Following trends in prescribing by using an identical methodology will be important for the future
assessment of the evidence for the use of regular, low-dose, sustained-release morphine for the
symptomatic reduction of chronic breathlessness.
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